" 312.20 
requirement for an ind. 
(a) a sponsor shall submit an ind to fda if the sponsor intends to conduct a clinical investigation with an investigational new drug that is subject to  312.2(a). 
(b) a sponsor shall not begin a clinical investigation subject to  312.2(a) until the investigation is subject to an ind which is in effect in accordance with  312.40. 
(c) a sponsor shall submit a separate ind for any clinical investigation involving an exception from informed consent under  50.24 of this chapter. such a clinical investigation is not permitted to proceed without the prior written authorization from fda. fda shall provide a written determination 30 days after fda receives the ind or earlier. 

